Corcept Therapeutics Reports Strong Revenue and Future Plans
Company Announcements

Corcept Therapeutics Reports Strong Revenue and Future Plans

Corcept Therapeutics ( (CORT) ) has shared an announcement.

Corcept Therapeutics reported a 48% boost in third-quarter revenue, reaching $182.5 million, and upgraded its 2024 revenue guidance. The company is on track to submit a New Drug Application for relacorilant, a promising treatment for Cushing’s syndrome, supported by successful trials showing significant patient improvements. With plans to release additional study data and a robust cash reserve, Corcept is poised for transformative growth in treating endocrinologic and oncologic conditions.

See more data about CORT stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyCorcept Therapeutics price target raised to $73.50 from $72 at Ladenburg
TipRanks Auto-Generated NewsdeskCorcept Therapeutics Reports Strong Q3 Results and Positive Trial Outcomes
TheFlyClosing Bell Movers: Microsoft, Meta both down about 3% despite earnings beats
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App